QIAGEN to Complement COVID-19 Testing Portfolio With Novel Kit That Simplifies and Accelerates PCR Analysis for Research Applications

  • Innovative QIAprep&amp technology integrates sample preparation and detection steps in one single kit
  • Streamlined workflow with sample prep under two minutes cuts costs, plastic usage and time to result to under one hour
  • Compatible with standard lab automation equipment, any assay and transport media

HILDEN, Germany & GERMANTOWN, Md.–(BUSINESS WIRE)–QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to launch a novel straightforward approach to viral RNA epidemiology that will significantly simplify and accelerate PCR analysis and remove key testing bottlenecks for SARS-CoV-2 and other RNA viruses.

QIAGEN’s innovative QIAprep&amp Viral RNA UM Kit combines a liquid-based sample preparation step completed in only two minutes with real-time PCR detection in a streamlined workflow that can be automated with standard lab equipment for any throughput, any assay and any reaction need from single to multiplex testing. The kit, which uses the most common transport media such as Universal Transport Media (UTMTM) as the starting material, includes both sample extraction components and optimized PCR reagents for only one procedure.

The streamlined workflow takes under one hour to deliver a result, compared to approximately three hours for standard extraction-based quantitative PCR processes and can handle up to 2,600 samples per eight-hour shift per cycler. As a result, labs can significantly accelerate the time to result and the frequency of viral testing. With only three small pipette tips needed per sample, the kit keeps plastic usage to a minimum, while providing significant cost savings by reducing reagent use and labor utilization.

Initial studies run by select public health research institutions have shown that the level of detection of the new QIAprep&amp Viral RNA UM Kit, when used with their assay, is similar to or better than regular PCR workflows, and that performance compares to standard public health protocols of the U.S. Centers of Disease Control (CDC), the World Health Organization (WHO) and others that use the gold standard for sample extraction.

Please find the full press release here

For an overview of QIAGEN’s coronavirus testing solutions, please visit http://www.qiagen.com/coronavirus


Investor Relations
John Gilardi +49 2103 29 11711
Phoebe Loh +49 2103 29 11457
e-mail: ir@QIAGEN.com

Public Relations
Thomas Theuringer +49 2103 29 11826
e-mail: pr@QIAGEN.com

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post